Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
187.86
+5.24 (2.87%)
Feb 21, 2025, 4:00 PM EST - Market closed
Krystal Biotech Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Krystal Biotech stock have an average target of 210, with a low estimate of 175 and a high estimate of 221. The average target predicts an increase of 11.79% from the current stock price of 187.86.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Krystal Biotech stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 5 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 8 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Hold Maintains $206 → $215 | Hold | Maintains | $206 → $215 | +14.45% | Feb 20, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $215 | Buy | Reiterates | $215 | +14.45% | Feb 20, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $212 → $218 | Strong Buy | Maintains | $212 → $218 | +16.04% | Feb 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $221 | Strong Buy | Reiterates | $221 | +17.64% | Feb 19, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $212 | Strong Buy | Maintains | $212 | +12.85% | Dec 18, 2024 |
Financial Forecast
Revenue This Year
295.62M
from 50.70M
Increased by 483.09%
Revenue Next Year
466.20M
from 295.62M
Increased by 57.70%
EPS This Year
2.81
from 0.39
Increased by 619.23%
EPS Next Year
6.00
from 2.81
Increased by 113.98%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 311.2M | 545.9M | 971.4M | |||
| Avg | 295.6M | 466.2M | 677.1M | |||
| Low | 274.4M | 377.3M | 492.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 513.9% | 84.7% | 108.4% | |||
| Avg | 483.1% | 57.7% | 45.2% | |||
| Low | 441.2% | 27.6% | 5.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 3.60 | 8.43 | 16.31 | |
| Avg | 2.81 | 6.00 | 9.54 | |
| Low | 1.88 | 2.95 | 4.29 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 823.5% | 200.6% | 171.7% | |
| Avg | 619.2% | 114.0% | 58.9% | |
| Low | 382.5% | 5.2% | -28.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.